The overall lack of longitudinal data on the second-generation tau PET tracers complicates the interpretation of individual prediction of elevated tau pathology and subsequent cognitive decline or conversion to prodromal or more advanced disease stages. The gene discussed is MAPT; the disease is Mental deterioration.